Amin Nassar

Amin Nassar, M.D., is a Clinical Fellow in Medical Oncology and Hematology at Yale School of Medicine. He holds a medical degree from the American University of Beirut and completed residency at Brigham and Women’s Hospital. His postdoctoral training under Professors David Kwiatkowski, Toni Choueiri, and Matthew Freedman at Harvard Medical School focused on genomic biomarkers across ancestral populations with cancer. Currently pursuing a PhD in tumor immunology at the Flavell lab, he is dedicated to becoming a physician-scientist specializing in thoracic oncology.

His research explores genetic and epigenetic factors influencing cancer outcomes, including tumor mutational burden (TMB) recalibration across ethnicities, KRAS mutations, and immune checkpoint inhibitor efficacy in diverse populations. He has authored over 50 peer-reviewed articles in high-impact journals like Nature Communications, Cancer Cell, and New England Journal of Medicine.

Nassar serves on editorial boards for Frontiers in Oncology, Molecular Biology Reports, and Translational Oncology, and has received awards including the ASH Achievement Award (2022) and Alpha Omega Alpha (2016). His work bridges clinical practice and research, emphasizing health equity and precision medicine.